Health ProductsNotice to Hospitals

BiCNU (carmustine for injection U.S.P.) Lyophilized Powder - Shortage of Canadian labelled BiCNU and replacement with U.S. labelled stock - Notice to Hospitals

· Published by Health Canada · Official notice

Details

Alert type: Notice to Hospitals
Category: Drugs
Issue: Supply, Important Safety Information
Audience: Healthcare Professionals
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Details

This is duplicated text of a letter from Bristol-Myers Squibb Canada. Contact the company for a copy of any references, attachments or enclosures.

Notice about Health Canada advisories

Notice to Hospitals - Health Canada Endorsed Important Information on BiCNU

September 3, 2013

Dear Healthcare Professional:

Please distribute this Notice to the Hospital Chief of Staff and post it in your institution.

Subject:  BiCNUFootnote 1 (carmustine for injection U.S.P.) Lyophilized Powder, 100 mg/vial DIN 00297763 
Shortage of Canadian labeled BiCNU and replacement with U.S. labeled stock

  • Bristol-Myers Squibb Canada (BMS) wishes to advise you of a shortage of Canadian labeled BiCNUFootnote 1 (carmustine for injection U.S.P.) Lyophilized Powder, 100 mg/vial (DIN 00297763). 
  • As a result, Canadian orders of BiCNU are being filled with U.S. labeled stock of BiCNU as outlined below. While most hospitals will not be impacted by this issue, hospitals supplied with U.S. labeled BiCNU will receive this notice.
  • As there are some differences in the product labeling, BMS also wishes to remind you that the U.S. labeled product must be used in accordance with the recommendations outlined in the Canadian Prescribing Information (PI) for BiCNU dated 30 June 2011.
BiCNU (carmustine) U.S. labeled stock
Component Lot Expiry
Carmustine vial CMCA3002 02/16
Diluent Ampule 2130 09/15
Kit 2C7010A 09/15

This temporary measure has been taken, with Health Canada's authorization, in order to ensure patients have uninterrupted access to BiCNU until supplies of Canadian labeled product are replenished. This measure is expected to last until October 2013.

Please note that while in Canada, BiCNU (carmustine) is sold under the BMS Canada label, in the U.S., BiCNU is sold under the Heritage Pharmaceuticals Inc. label.

BMS wishes to confirm that, with the exception of the labeling, the BiCNU (carmustine) vials and diluent ampules supplied in the U.S. labeled trade packs are identical to those currently distributed on the Canadian marketplace.

As there are some differences in the product labeling, BMS also wishes to remind you that the U.S. labeled product must be used in accordance with the recommendations outlined in the Canadian Prescribing Information (PI) for BiCNU dated 30 June 2011. In particular, the approved Canadian dosing recommendations outlined below should be strictly adhered to:

  • The recommended dose of BiCNU as a single agent in previously untreated patients is 200 mg/m² intravenously every 6 weeks. This may be given as a single dose or divided into daily injections such as 100 mg/m² on 2 successive days.
  • When BiCNU is used in combination with other myelosuppressive drugs or in patients in whom bone marrow reserve is depleted, the doses should be adjusted accordingly.
  • Doses subsequent to the initial dose should be adjusted according to the hematologic response of the patient to the preceding dose.

The full Canadian PM for BiCNU, prepared for health professionals can be found at: www.bmscanada.ca or by contacting Bristol-Myers Squibb Canada at 1-866-463-6267. In addition, to ensure rapid access to the Canadian labeled recommendations, the Canadian PI is included in each shipment of U.S. labeled BiCNU. As a reminder, in Canada, BiCNU (carmustine) is indicated as palliative therapy to surgery and radiotherapy or in combination therapy with other chemotherapeutic agents in primary brain tumors, malignant lymphomas, multiple myeloma, malignant melanoma (disseminated) and gastrointestinal carcinoma.

Managing marketed health product-related adverse reactions depends on healthcare professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-market adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any serious or unexpected adverse reactions possibly related to the use of BiCNU should be reported to Bristol-Myers Squibb Canada or Health Canada at the following addresses:

Bristol-Myers Squibb Canada
2344 Alfred-Nobel, suite 300
Montréal, Québec
H4S 0A4
Tel : 866-463-6267

You can also report any suspected adverse reactions associated with the use of health products to Health Canada by:

  • Calling toll-free at 1-866-234-2345, or
     
  • Visiting MedEffect Canada's Web page on Adverse Reaction Reporting for information on how to report online, by mail or by fax.

For other health product inquiries related to this communication, please contact Health Canada at:
Health Products and Food Branch Inspectorate
E-mail: GMP_Questions_BPF@hc-sc.gc.ca
Telephone: 613-957-1492
Fax: 613-957-6709

If you have any questions regarding this communication, please contact Customer Services at 1-800-267-0005 (8:30 a.m. to 5:00 p.m. Eastern Standard Time). For medical queries, please call Medical Services at 1-866-463-6267.

Original signed by

Vicky Esposito
VIce-President, Regulatory Affairs & QA;

Footnotes

Footnote 1

TM of Bristol-Myers Squibb Company used under licence by Bristol-Myers Squibb Canada

Return to footnote 1 referrer

Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime